Oksikonazol

When ATH:
D01AC11

Characteristic.

The antifungal agent for topical use. Imidazole. Oxiconazole nitrate - almost white crystalline powder. Soluble in methanol, hard soluble in ethanol, chloroform and acetone, very slightly soluble in water. Molecular weight - 492,15.

Pharmacological action.
Antifungal.

Application.

The treatment of fungal infections of the skin (including hairy areas), caused by susceptible pathogens.

Contraindications.

Hypersensitivity, Children up to age 6 years.

Pregnancy and breast-feeding.

Not recommended for use during pregnancy (adequate and well-controlled studies in pregnant women have not performed) and breastfeeding (oxiconazole nitrate enters the breast milk).

Side effects.

From 955 patients, primenyavshih oxiconazole nitrate Vide 1% cream, in clinical trials in 41 patient (4,3%) observed side effects, associated with drug therapy, including itching (1,6%), burning (1,4%), irritation (0,4%), contact type allergy (0,4%), folliculitis (0,3%), eczema (0,2%), papules (0,1%), cracks (0,1%), maceration (0,1%), rash (0,1%), pricking (0,1%), nodules (0,1%).

Overdose.

Cases of overdose have been identified in humans. Symptoms Accidental ingestion: nausea, vomiting. Treatment: gastric lavage, simptomaticheskaya therapy.

Experimental conditions (a group of 40 male and female rats) when applied 5% cream approximately 10% calculation of the body surface 1 g/kg for 35 days were marked: pronounced skin inflammation and 3 deaths.

Dosing and Administration.

Outwardly, for the night. The cream is applied to the affected area 1-2 times a day. Duration of the course: 2 week - when the body's skin mycosis, 1 months - in mycosis stop and for a further 1-2 weeks after full recovery to prevent recurrence.

Precautions.

Avoid contact with the mucous membrane of the eye. With the development of hypersensitivity reactions or irritation oxiconazole nitrate treatment should be discontinued.

Cautions.

Do not use with other drugs for local use without consulting your doctor.

Cooperation

Active substanceDescription of interaction
SimvastatinFKV. FMR. Against the background of systemic effects oxiconazole inhibited CYP3A4, zamedlyaetsya biotransformation, increased plasma concentrations and increases the risk of myopathy and rhabdomyolysis.

Back to top button